SanofiSanofi’s tolebrutinib fails Phase III in PPMS, while FDA postpones decision on targeted therapy approval for nrSPMS.
Tag Archive for: multiple sclerosis
lkov - adobe stock photoNovartis AG has reported a clinical milestone in the treatment of Sjögren’s syndrome, with its BAFF receptor blocker Ianalumab (VAY736) becoming the first investigational therapy to demonstrate a statistically significant reduction in disease activity in pivotal Phase III trials, as measured by the ESSDAI score.
Immunic/Nela DornerMultiple sclerosis is currently an incurable, chronic autoimmune disease. While it is possible to effectively manage the feared relapses with existing therapies, novel approaches aim to provide important protection against long-term impairments.
Innerstream - wikimedia.orgRoche’s fenebrutinib demonstrated near-complete suppression of disease activity and disability progression after one year in patients with relapsing multiple sclerosis
Roche’s bruton’s tyrosine kinas blocker fenebrutinib has met all endpoints in proof-of-concept study with patients suffering from relapsing-remitting multiple sclerosis.
French and British scientists have revealed insight into how a critical immune regulatory pathway contributes to the development of multiple sclerosis (MS), potentially paving the way toward future immunotherapies for the debilitating condition.